Full Paper
(ddd, J=7.2, 14.7, 25.7 Hz, 3H), 6.86 (dd, J=1.4, 7.5 Hz, 1H), 4.37
(s, 2H), 4.30 (d, J=13.7 Hz, 1H), 4.13 (d, J=13.7 Hz, 1H), 3.51 (ddt,
J=5.5, 6.8, 9.4 Hz, 1H), 3.09 (dd, J=6.9, 9.4 Hz, 1H), 2.98 (dd, J=
5.2, 13.6 Hz, 1H), 2.87 (dd, J=5.8, 9.4 Hz, 1H), 2.69 (dd, J=9.6,
13.6 Hz, 1H), 1.99 ppm (s, 3H); 13C NMR (126 MHz, CDCl3): d=
136.3, 135.4, 135.0, 134.4, 130.6, 130.1, 128.9, 128.7, 128.7, 128.7,
128.2, 128.1, 127.1, 126.1, 55.7, 50.7, 50.6, 49.6, 36.8, 19.1 ppm; IR
(film): n˜ =1283, 1164 cmꢀ1; MS (ESI): m/z calcd for C24H26N2O2S:
407.1788 [M+H]+; found: 407.1790.
5-Benzyl-2-(4-methoxybenzyl)-3-(4-methylbenzyl)-1,2,5-thiadia-
zolidine-1,1-dioxide (2i): The general procedure was employed for
the coupling of 1c (87 mg, 0.25 mmol) and para-tolyl trifluorome-
thanesulfonate (54 mL, 0.30 mmol) using a catalyst composed of
Pd(OAc)2 (1.1 mg, 0.005 mmol) and RuPhos (5.8 mg, 0.0125 mmol).
This procedure afforded 95 mg (87%) of the product as a pale-
yellow solid. M.p. 109–1138C; 1H NMR (400 MHz, CDCl3): d=7.42–
7.25 (m, 7H), 6.99 (d, J=7.8 Hz, 2H), 6.92–6.86 (m, 2H), 6.79 (d, J=
7.9 Hz, 2H), 4.36–4.21 (m, 3H), 4.01 (d, J=13.8 Hz, 1H), 3.81 (s, 3H),
3.49–3.37 (m, 1H), 3.02 (dd, J=7.0, 9.4 Hz, 1H), 2.86 (dd, J=5.0,
13.5 Hz, 1H), 2.78 (dd, J=6.2, 9.4 Hz, 1H), 2.56 (dd, J=9.5, 13.5 Hz,
1H), 2.26 ppm (s, 3H); 13C NMR (126 MHz, CDCl3): d=159.5, 136.5,
135.0, 133.0, 130.4, 129.4, 129.0, 128.7, 128.6, 128.1, 127.3, 114.0,
57.1, 55.3, 50.6, 50.3, 49.5, 39.0, 21.0 ppm; IR (film): n˜ =1281,
1158 cmꢀ1; MS (ESI): m/z calcd for C25H28N2O3S: 437.1893 [M+H]+;
found: 437.1885.
2,5-Dibenzyl-3-(cyclohex-1-en-1-ylmethyl)-1,2,5-thiadiazolidine-
1,1-dioxide (2 f): The general procedure was employed for the
coupling of 1a (79 mg, 0.25 mmol) and 1-cyclohexenyl trifluorome-
thanesulfonate (52 mL, 0.30 mmol) using a catalyst composed of
Pd(OAc)2 (1.1 mg, 0.005 mmol) and BrettPhos (6.7 mg,
0.0125 mmol). This procedure afforded 89 mg (90%) of the product
1
as a pale-yellow solid. M.p. 66–688C; H NMR (500 MHz, CDCl3): d=
5-Benzyl-2-methyl-3-(3-(trifluoromethyl)benzyl)-1,2,5-thiadiazoli-
dine-1,1-dioxide (2j): The general procedure was employed for
the coupling of 1d (60 mg, 0.25 mmol) and 3-trifluoromethylphen-
yl trifluoromethanesulfonate (60 mL, 0.30 mmol) using a catalyst
composed of Pd(OAc)2 (1.1 mg, 0.005 mmol) and RuPhos (5.8 mg,
0.0125 mmol). This procedure afforded 78 mg (81%) of the product
as a pale-yellow oil. 1H NMR (500 MHz, CDCl3): d=7.52 (d, J=
7.8 Hz, 1H), 7.43 (t, J=7.7 Hz, 1H), 7.40 (d, J=1.6 Hz, 1H), 7.38–
7.29 (m, 6H), 4.31 (d, J=13.9 Hz, 1H), 3.99 (d, J=13.9 Hz, 1H), 3.44
(m, 1H), 3.16 (dd, J=6.9, 9.4 Hz, 1H), 3.12 (dd, J=5.7, 13.6 Hz, 1H),
2.85–2.78 (m, 2H), 2.75 ppm (s, 3H); 13C NMR (126 MHz, CDCl3): d=
136.9, 134.8, 132.7, 131.2 (q, J=33.8 Hz), 129.3, 128.7, 128.6, 128.2,
125.8, 124.1, 123.9 (q, J=272.4 Hz), 59.6, 50.8, 49.5, 38.8, 33.6 ppm;
IR (film): n˜ =1242, 1127 cmꢀ1; MS (ESI): m/z calcd for C18H19F3N2O2S:
385.1192 [M+H]+; found: 385.1193.
7.45 (d, J=7.0 Hz, 2H), 7.42–7.29 (m, 8H), 5.33 (s, 1H), 4.49 (d, J=
15.0 Hz, 1H), 4.36 (d, J=13.8 Hz, 1H), 4.26 (d, J=15.0 Hz, 1H), 4.05
(d, J=13.8 Hz, 1H), 3.47–3.36 (m, 1H), 3.21 (dd, J=7.0, 9.4 Hz, 1H),
2.81 (dd, J=6.6, 9.4 Hz, 1H), 2.23 (dd, J=2.2, 14.0 Hz, 1H), 2.04
(dd, J=9.7, 13.6 Hz, 1H), 1.94–1.80 (m, 2H), 1.73–1.59 (m, 1H),
1.59–1.33 ppm (m, 5H); 13C NMR (126 MHz, CDCl3): d=135.8, 135.7,
135.1, 132.2, 128.7, 128.7, 128.6, 128.0, 127.9, 125.5, 54.8, 50.8, 50.6,
49.9, 41.9, 28.3, 25.1, 22.6, 22.0 ppm; IR (film): n˜ =1286, 1154 cmꢀ1
;
MS (ESI): m/z calcd for C23H28N2O2S: 397.1944 [M+H]+; found:
397.1949.
(E)-2,5-Dibenzyl-3-(undec-2-en-1-yl)-1,2,5-thiadiazolidine-1,1-di-
oxide (2g): The general procedure was employed for the coupling
of 1a (79 mg, 0.25 mmol) and (E)-dec-1-en-1-yl trifluoromethane-
sulfonate (101 mL, 0.35 mmol, 5:1 mixture of E/Z isomers) using
LiOtBu (32 mg, 0.40 mmol) and a catalyst composed of Pd(OAc)2
(1.1 mg, 0.005 mmol) and tBuDavePhos (4.3 mg, 0.0125 mmol). This
procedure afforded 90 mg (79%) of the product as a yellow oil.
The compound was judged to be a 5:1 mixture of E/Z isomers by
1H NMR spectroscopic analysis. Data are given for the major
E isomer: 1H NMR (500 MHz, CDCl3): d=7.51–7.42 (m, 2H), 7.42–
7.29 (m, 8H), 5.44 (dt, J=7.4, 11.0 Hz, 1H), 5.16–5.06 (m, 1H), 4.51
(d, J=15.1 Hz, 1H), 4.36 (d, J=13.7 Hz, 1H), 4.26 (d, J=14.8 Hz,
1H), 4.02 (d, J=13.7 Hz, 1H), 3.33 (ddd, J=5.6, 9.2, 11.1 Hz, 1H),
3.22 (dd, J=7.0, 9.3 Hz, 1H), 2.79 (dd, J=7.1, 9.3 Hz, 1H), 2.27
(dddd, J=5.5, 7.5, 13.5, 15.9 Hz, 1H), 2.16 (dt, J=8.4, 15.2 Hz, 1H),
1.81 (tt, J=6.9, 12.9 Hz, 2H), 1.35–1.18 (m, 12H), 0.91 ppm (q, J=
6.5 Hz, 3H); 13C NMR (126 MHz, CDCl3): d=135.7, 134.9, 134.4,
128.7, 128.7, 128.7, 128.6, 128.1, 128.0, 122.1, 56.3, 50.9, 50.6, 49.6,
31.9, 30.5, 29.5, 29.4, 29.3, 29.3, 27.4, 22.7 ppm, 14.1; IR (film): n˜ =
1304, 1164 cmꢀ1; MS (ESI): m/z calcd for C27H38N2O2S: 455.2727
[M+H]+; found: 455.2735.
5-Benzyl-2-(tert-butyl)-3-(4-methoxybenzyl)-1,2,5-thiadiazoli-
dine-1,1-dioxide (2k): The general procedure was employed for
the coupling of 1e (71 mg, 0.25 mmol) and 4-methoxyphenyl tri-
fluoromethanesulfonate (54 mL, 0.30 mmol) using a catalyst com-
posed of Pd(OAc)2 (1.1 mg, 0.005 mmol) and RuPhos (5.8 mg,
0.0125 mmol). This procedure afforded 90 mg (93%) of the product
as a white solid. M.p. 104–1068C; 1H NMR (500 MHz, CDCl3): d=
7.47–7.32 (m, 5H), 6.79 (d, J=8.6 Hz, 2H), 6.71 (d, J=8.6 Hz, 2H),
4.46 (d, J=13.5 Hz, 1H), 3.77 (d, J=13.6 Hz, 1H), 3.75 (s, 3H), 3.54
(dddd, J=1.3, 4.1, 5.8, 10.4 Hz, 1H), 2.98–2.78 (m, 4H), 1.53 ppm (s,
9H); 13C NMR (126 MHz, CDCl3): d=158.4, 135.4, 130.2, 129.3,
128.8, 128.7, 128.1, 114.0, 57.8, 55.4, 55.2, 49.0, 47.1, 40.8,
˜
28.2 ppm; IR (film): n=1279, 1142 cmꢀ1; MS (ESI): m/z calcd for
C21H28N2O3S: 389.1893 [M+H]+; found: 389.1893.
3,5-Dibenzyl-2-(4-methoxyphenyl)-1,2,5-thiadiazolidine-1,1-diox-
ide (2l): The general procedure was employed for the coupling of
1-allyl-1-benzyl-3-(4-methoxyphenyl)sulfamide
0.25 mmol) and phenyl trifluoromethanesulfonate (49 mL,
0.30 mmol) using catalyst composed of Pd(OAc)2 (1.1 mg,
(1 f;
83 mg,
2-Benzyl-3-(4-chlorobenzyl)-5-methyl-1,2,5-thiadiazolidine-1,1-
dioxide (2h): The general procedure was employed for the cou-
pling of 1b (60 mg, 0.25 mmol) and 4-chlorophenyl trifluorometha-
nesulfonate (52 mL, 0.30 mmol) using a catalyst composed of
Pd(OAc)2 (1.1 mg, 0.005 mmol) and RuPhos (5.8 mg, 0.0125 mmol).
This procedure afforded 68 mg (78%) of the product as a white
a
0.005 mmol) and tBuXPhos (5.3 mg, 0.0125 mmol). This procedure
afforded 91 mg (89%) of the product as a yellow solid. M.p. 95–
978C; 1H NMR (500 MHz, CDCl3): d=7.45–7.30 (m, 7H), 7.29–7.19
(m, 3H), 7.07–6.97 (m, 4H), 4.41 (d, J=14.0 Hz, 1H), 4.21–4.12 (m,
1H), 4.06 (d, J=14.0 Hz, 1H), 3.85 (s, 3H), 3.24 (dd, J=6.5, 9.2 Hz,
1H), 3.03 (dd, J=7.6, 9.4 Hz, 1H), 3.00 (dd, J=4.2, 13.8 Hz, 1H),
2.71 ppm (dd, J=9.5, 13.7 Hz, 1H); 13C NMR (126 MHz, CDCl3): d=
159.2, 135.5, 134.9, 129.2, 128.8, 128.7, 128.7, 128.6, 128.2, 128.1,
127.0, 115.0, 58.6, 55.5, 51.2, 49.7, 38.7 ppm; IR (film): n˜ =1289,
1157 cmꢀ1; MS (ESI): m/z calcd for C23H24N2O3S: 409.1580 [M+H]+;
found: 409.1577.
1
solid. M.p. 133–1358C; H NMR (500 MHz, CDCl3): d=7.41–7.36 (m,
4H), 7.36–7.31 (m, 1H), 7.23 (d, J=8.3 Hz, 2H), 6.92 (d, J=8.3 Hz,
2H), 4.43 (d, J=14.9 Hz, 1H), 4.25 (d, J=14.9 Hz, 1H), 3.51 (dtd, J=
5.2, 6.9, 9.3 Hz, 1H), 3.17 (dd, J=7.0, 9.3 Hz, 1H), 2.89 (dd, J=5.2,
13.6 Hz, 1H), 2.86 (dd, J=6.8, 9.3 Hz, 1H), 2.73 (s, 3H), 2.61 ppm
(dd, J=9.3, 13.6 Hz, 1H); 13C NMR (126 MHz, CDCl3): d=135.3,
134.5, 132.9, 130.4, 128.9, 128.8, 128.7, 128.1, 57.1, 52.5, 51.2, 39.0,
33.2 ppm; IR (film): n˜ =1297, 1149 cmꢀ1; MS (ESI): m/z calcd for
C17H19ClN2O2S: 351.0929 [M+H]+; found: 351.0926.
3-(Benzo[d][1,3]dioxol-5-ylmethyl)-2-benzyl-5-methyl-1,2,5-thia-
diazolidine-1,1-dioxide (2m): The general procedure was em-
&
&
Chem. Eur. J. 2014, 20, 1 – 10
6
ꢀ 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ÝÝ These are not the final page numbers!